Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Alan Hartman

Partner
 
Alan Hartman has over 25 years of investment banking experience, having advised on many of the transactions that have helped transformed the healthcare sector over that time. Over the course of his career, Mr. Hartman has advised on over $800 billion of transactions, and has established himself as a leading advisor in the healthcare industry. He has advised in some of the largest and most complex transactions across every aspect of the industry, including:

  • Large Pharma  - Advised Pfizer in multiple transactions including its $68bn acquisition of Wyeth, its $14bn acquisition of Medivation, its $5bn acquisition of Anacor, its $12bn sale of its nutritional business to Nestlé and its $18bn OTC JV with Glaxo; Astra Zeneca in its $15bn acquisition of MedImmune; Merck in its $3bn acquisition of Antelliq and Novartis in the $1bn sale of certain generic assets
  • Biotech - Advised Pharmacyclics in its $21bn sale to Abbvie; Immunex in its $16bn sale to Amgen and Onyx in its $10bn sale to Amgen; Biogen in its defense against Icahn and acquisition of control of Tysabri for $3bn; InterMune in its $9bn sale to Roche; Receptos in its $8bn sale to Celgene; AveXis in its $8bn sale to Novartis; Spark in its $5bn sale to Roche; Tesaro in its $5bn sale to Glaxo and Celgene in its $3bn acquisition of Pharmion
  • Specialty Pharma  - Mylan in its $40bn merger with Pfizer’s Upjohn division and in $30bn of other acquisitions; Salix’s $16bn sale to Valeant and Questcor in its $6bn sale to Mallinckrodt
  • Healthcare Services - The buyout group led by KKR and Bain in the $33bn acquisition of HCA; Omnicare in its $13bn sale to CVS; Alliance Boots in its two step sale to Walgreens for $25bn; Bergen Brunswig in its $4bn merger with Amerisource
  • Healthcare REITs - Advised Ventas on over $20bn of deals over a 15 year period, including the acquisition of NHP for $7bn and the spin-off of Care Capital for $4bn
  • Medical Devices - Represented Boston Scientific in its $25bn hostile acquisition of Guidant
Mr. Hartman joined Centerview in 2009 after 16 years at Merrill Lynch, where he was head of Americas Mergers & Acquisitions. He received a BS in Economics from the Wharton School of the University of Pennsylvania and a JD from Harvard Law School. He spent four years as a corporate attorney at Skadden Arps prior to joining Merrill Lynch. He was twice named one of the “Dealmakers of the Year” by Dealmaker Magazine. He is married with three children.


 


 


Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Cision Ltd.
Announced: Q4 2019
Value: $2.7 billion
Status: Pending

Financial advisor to Cision on its sale to an affiliate of Platinum Equity
View All
New York

Centerview Partners LLC
31 West 52nd Street
22nd Floor
New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax
London

Centerview Partners UK LLP
100 Pall Mall
3rd Floor
London SW1Y 5NQ,

02074099700 | Tel
02074099704 | Fax
San Francisco

Centerview Partners LLC
555 California Street
Suite 4300
San Francisco, CA 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax
Los Angeles

Centerview Partners LLC
1999 Avenue of the Stars
Suite 3030
Los Angeles, CA 90067

(424) 230-5950 | Tel
(424) 230-5951 | Fax
Palo Alto

Centerview Partners LLC
600 Ramona St.
Suite 300
Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax

Copyright © 2008 - 2019 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC